Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

morning brief

- PMLiVE

Witty says Chinese bribery probe will impact GSK

CEO says company’s performance in China will be affected

National Institute for Health and Care Excellence NICE logo

NICE gives final backing to drugs from Bayer, GSK and Otsuka

Eylea, Revolade and Abilify all recommended for NHS use

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

GSK concedes execs may have broken Chinese law

President of international operations suggests senior execs were involved in bribery scandal

- PMLiVE

Four GSK execs held in China bribery probe

Ministry of Public Security says company has dispensed nearly $500m in bribes since 2007

China flag thumb

GSK staff ‘confess to bribery’, says China

Government claims staff offered kickbacks to state officials and doctors

- PMLiVE

GSK signs $500m-plus technology deal with Immunocore

Will make use of ImmTAC technology to activate immune system to kill cancerous or infected cells

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

- PMLiVE

GSK’s Botox sales in China under scrutiny says WSJ

Newspaper says it has reviewed company documents that discuss giving kickbacks to doctors to prescribe Botox

- PMLiVE

GSK’s Philip Thomson named Communiquetor of the Year

Recognised for stewardship of pharma company's global communications team

- PMLiVE

GSK’s personalised cancer drug Tafinlar set for European approval

Regulatory advisors recommend the melanoma drug be licensed

- PMLiVE

GSK’s muscular dystrophy drug ‘a breakthrough’ says FDA

The antisense oligonucleotide is being developed by GlaxoSmithKline and Prosensa

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links